Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Alimentary Pharmacology & Therapeutics|April 12, 2019
Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levelsAmanda J Nicoll, Stuart K Roberts, Ricky Lim, et al.
Journal of Gastroenterology and Hepatology|December 19, 2023
Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of carePaul J Clark, Patricia C Valery, Simone I Strasser, et al.
Digestive Diseases and Sciences|May 13, 2022
Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment CohortPaul J Clark, Patricia C Valery, Simone I Strasser, et al.
BMC Gastroenterology|July 12, 2022
Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-upPaul J Clark, Patricia C Valery, James Ward, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 15, 2021
Management, outcomes and survival of an Australian IgG4-SC cohort: The MOSAIC studyWilliam Kemp, Ammar Majeed, Joanne Mitchell, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 21, 2017
Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard TherapyStuart K Roberts, Ricky Lim, Simone Strasser, et al.
Antiviral Therapy|April 20, 2017
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL studyJohn Lubel, Simone Strasser, Katherine A Stuart, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2020
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure CharacteristicsTimothy Papaluca, Stuart K Roberts, Simone I Strasser, et al.
Hepatology Communications|April 1, 2026
The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensusAvik Majumdar, Jacinta Holmes, Stuart K Roberts, et al.
Hepatology International|March 3, 2026
Australian best practice recommendations for transjugular intrahepatic portosystemic shunt (TIPS) in portal hypertension: a consensus statementEric Kalo, Jacinta Holmes, Purnima Bhat, et al.
Pageof 6